Rush J E, Lyle P A
Cardiovascular Renal Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Am J Med. 1988 Sep 23;85(3B):55-9. doi: 10.1016/0002-9343(88)90352-x.
The safety and tolerability of lisinopril have been assessed in 1,734 hypertensive patients treated with the agent in a number of clinical trials. Here we compare the clinical and laboratory adverse experiences in younger (under 55 years old) and older (at least 55 years old) patients treated with lisinopril monotherapy. The incidence of adverse experiences in these older patients was similar to that in the younger patients. A comparison also was made of clinical adverse experience data for older hypertensive patients treated either with lisinopril monotherapy or with various control agents (atenolol, metoprolol, and hydrochlorothiazide) in double-blind controlled studies. In these studies, the clinical adverse experience incidences and discontinuation percentages seen in the older patients treated with lisinopril were comparable to the data from the patients treated with the control agents. Thus, lisinopril is generally well-tolerated in older hypertensive patients, and should be considered a therapeutic option in the management of these patients.
在多项临床试验中,已有1734例接受赖诺普利治疗的高血压患者对该药的安全性和耐受性进行了评估。在此,我们比较了接受赖诺普利单一疗法治疗的年轻患者(55岁以下)和老年患者(至少55岁)的临床和实验室不良经历。这些老年患者的不良经历发生率与年轻患者相似。我们还对在双盲对照研究中接受赖诺普利单一疗法或各种对照药物(阿替洛尔、美托洛尔和氢氯噻嗪)治疗的老年高血压患者的临床不良经历数据进行了比较。在这些研究中,接受赖诺普利治疗的老年患者的临床不良经历发生率和停药百分比与接受对照药物治疗的患者的数据相当。因此,赖诺普利在老年高血压患者中通常耐受性良好,应被视为这些患者治疗的一种选择。